Bayesian Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$411K Buy
+9,200
New +$523K 0.33% 87
2025
Q4
– Sell
-24,715
Closed -$1.62M – 326
2025
Q3
$1.62M Buy
24,715
+8,115
+49% +$396K 0.33% 92
2025
Q2
$656K Buy
16,600
+8,100
+95% +$265K 0.1% 243
2025
Q1
$256K Buy
+8,500
New +$278K 0.04% 432
2023
Q2
– Sell
-21,227
Closed -$759K – 929
2023
Q1
$759K Buy
+21,227
New +$797K 0.09% 284
2022
Q3
– Sell
-9,063
Closed -$336K – 854
2022
Q2
$336K Buy
+9,063
New +$342K 0.06% 437
2020
Q2
– Sell
-5,300
Closed -$251K – 639
2020
Q1
$251K Buy
5,300
+1,815
+52% +$101K 0.05% 520
2019
Q4
$211K Buy
+3,485
New +$208K 0.04% 523
2017
Q1
– Sell
-10,138
Closed -$485K – 543
2016
Q4
$485K Buy
+10,138
New +$401K 0.12% 314

Other funds holding IONS

Bayesian Capital Management's IONS Position: Q3 2026 in Review

Bayesian Capital Management opened a new position in Ionis Pharmaceuticals (IONS) in Q3 2026: 9,200 shares worth $411K. The stake represents 0.33% of the portfolio and ranks #87 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in IONS as recently as Q3 2025.

Bayesian Capital Management first reported a position in IONS in Q4 2016 and has held it in 9 quarters since. The position peaked at $1.62M in Q3 2025. 465 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Bayesian Capital Management held 9,200 shares of Ionis Pharmaceuticals worth $411K as of Q3 2026.
  • Ionis Pharmaceuticals was a new Bayesian Capital Management position in Q3 2026.
  • Ionis Pharmaceuticals made up 0.33% of Bayesian Capital Management's portfolio in Q3 2026, its #87 holding.
  • Bayesian Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 9 quarters since.
  • Bayesian Capital Management's Ionis Pharmaceuticals position peaked at $1.62M in Q3 2025.
  • 465 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Bayesian Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.